XL765 (SAR245409) + Temozolomide
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mixed Gliomas
Conditions
Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme
Trial Timeline
Aug 1, 2008 → Feb 1, 2013
NCT ID
NCT00704080About XL765 (SAR245409) + Temozolomide
XL765 (SAR245409) + Temozolomide is a phase 1 stage product being developed by Sanofi for Mixed Gliomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00704080. Target conditions include Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00704080 | Phase 1 | Completed |
Competing Products
20 competing products in Mixed Gliomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bempedoic acid 180 mg tablet | Daiichi Sankyo | Approved | 85 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Lurasidone + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| MK-0524A + Atorvastatin + Simvastatin | Merck | Phase 3 | 77 |
| Inclisiran + Matching Placebo for Inclisiran | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Approved | 85 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Atorvastatin + Evolocumab | Amgen | Phase 3 | 76 |
| Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin | Amgen | Phase 3 | 76 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Evolocumab + Atorvastatin | Amgen | Phase 3 | 76 |
| Evolocumab + Standard of Care | Amgen | Phase 3 | 76 |
| torcetrapib/atorvastatin + atorvastatin | Pfizer | Phase 3 | 76 |
| Bococizumab + Placebo | Pfizer | Phase 3 | 76 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| IBI306 + placebo + placebo + IBI306 | Innovent Biologics | Phase 3 | 76 |
| KarXT | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT | Bristol Myers Squibb | Phase 3 | 76 |
| Gemcitabine + Oxaliplatin | Sanofi | Phase 2 | 51 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |